ReviewAnales del sistema sanitario de Navarra2022
[Leishmaniasis in Navarra, Spain (1976-2018): an update].
Review in Anales del sistema sanitario de Navarra, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Agreement Document for the Study of Leishmaniasis from a One Health Approach in Spain.Tropical medicine and infectious disease · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis is endemic in countries of the Mediterranean area. In this study, the information available on leishmaniasis in Navarra in the period 1976-2018 and in the bordering regions was collected, along with an overview of the situation of this disease at the national level, from the vector to humans. Aragón exhibited a lower incidence rate in the last ten years (2008-2018) compared to the previous decade, while Navarra and La Rioja have almost doubled the number of cases per 100,000 inhabitants and, likewise, incidence in the Basque Country has also increased. At the national level, since 2015, such an increase has become significant due to the inclusion of human leishmaniasis as a mandatory notifiable disease. Currently in Spain, although the incidence of human leishmaniasis is not a situation of high concern, it is however a reality. Therefore, it is necessary to monitor its evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.